Ameritas Investment Partners’s Exagen XGN Stock Holding History

Ameritas Investment Partners’s Portfolio XGN Stock Details XGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-849	Closed	-$7K	–	3254
2022 Q1	$7K	Hold	849	–	–	﹤0.01%	2903
2021 Q4	$10K	Hold	849	–	–	﹤0.01%	2908
2021 Q3	$12K	Hold	849	–	–	﹤0.01%	2898
2021 Q2	$13K	Buy	849 +564	+198%	+$8.65K	﹤0.01%	2894
2021 Q1	$5K	Hold	285	–	–	﹤0.01%	3009
2020 Q4	$4K	Hold	285	–	–	﹤0.01%	3010
2020 Q3	$3K	Hold	285	–	–	﹤0.01%	3052
2020 Q2	$4K	Hold	285	–	–	﹤0.01%	3005
2020 Q1	$5K	Hold	285	–	–	﹤0.01%	2836
2019 Q4	$7K	Buy	+285	New	+$5.07K	﹤0.01%	2854

Other funds holding XGN

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SAM

Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Ameritas Investment Partners's XGN Position: Q2 2022 in Review

Ameritas Investment Partners sold out of Exagen (XGN) in Q2 2022, closing a stake of 849 shares — an estimated $7K sold.

Ameritas Investment Partners first reported a position in XGN in Q4 2019 and held it in 10 quarters. The position peaked at $13K in Q2 2021. 47 funds tracked by Wall St. Rank hold XGN as of Q2 2022.

Ameritas Investment Partners reported no remaining Exagen position as of Q2 2022 after selling out during the quarter.
Ameritas Investment Partners sold 849 Exagen shares in Q2 2022, an estimated $7K.
Ameritas Investment Partners first reported a position in Exagen in Q4 2019 and held it in 10 quarters.
Ameritas Investment Partners's Exagen position peaked at $13K in Q2 2021.
47 funds tracked by Wall St. Rank held Exagen as of Q2 2022.

Based on Ameritas Investment Partners's 13F filing for Q2 2022, filed 12 Aug 2022.